Zhang Xu, Ping Shuai, Wang Anni, Li Can, Zhang Rui, Song Zimu, Gao Caibin, Wang Feng
Department of Neurosurgery, Baoding No.1 Central Hospital, Baoding, People's Republic of China.
Department of Orthopaedics, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Int J Gen Med. 2021 Nov 23;14:8611-8620. doi: 10.2147/IJGM.S335052. eCollection 2021.
Gliomas are prevalent primary intracerebral malignant tumors. Increasing evidence indicates an association between the immune signature and Grade II/III glioma prognosis. Thus, we aimed to develop an immune-related gene pair (IRGP) signature that can be used as a prognostic tool in Grade II/III glioma.
The gene expression levels and clinical information of Grade II/III glioma patients were collected from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases. The TCGA data were randomly divided into a training cohort (n = 249) and a validation cohort (n = 162), and a CGGA dataset served as an external validation group (n = 605). IRGPs significantly associated with prognosis were selected by Cox regression. Gene set enrichment analysis and filtration were performed with the IRGPs.
Within a set of 1991 immune genes, 8 IRGPs including 15 unique genes that significantly affect survival constituted a gene signature. In the validation datasets, the IRGP signature significantly stratified patients with Grade II/III glioma into low- and high-risk groups ( < 0.001), and the IRGP index was found to be an independent prognostic factor through univariate and multivariate analyses ( < 0.05). Additionally, 26 functional pathways were identified through the intersection of Gene Set Enrichment Analysis (GSEA) and Gene Ontology (GO) enrichment analysis.
The IRGP signature demonstrated good prognostic value for Grade II/III gliomas, which may provide new insights into individual treatment for glioma patients. The IRGPs might function through the identified 26 functional pathways.
胶质瘤是常见的原发性脑内恶性肿瘤。越来越多的证据表明免疫特征与II/III级胶质瘤的预后之间存在关联。因此，我们旨在开发一种免疫相关基因对（IRGP）特征，可作为II/III级胶质瘤的预后工具。
从癌症基因组图谱（TCGA）和中国胶质瘤基因组图谱（CGGA）数据库收集II/III级胶质瘤患者的基因表达水平和临床信息。TCGA数据被随机分为训练队列（n = 249）和验证队列（n = 162），CGGA数据集作为外部验证组（n = 605）。通过Cox回归选择与预后显著相关的IRGPs。使用IRGPs进行基因集富集分析和筛选。
在一组1991个免疫基因中，8个IRGPs（包括15个显著影响生存的独特基因）构成了一个基因特征。在验证数据集中，IRGP特征将II/III级胶质瘤患者显著分层为低风险和高风险组（<0.001），并且通过单变量和多变量分析发现IRGP指数是一个独立的预后因素（<0.05）。此外，通过基因集富集分析（GSEA）和基因本体（GO）富集分析的交集确定了26条功能途径。
IRGP特征对II/III级胶质瘤具有良好的预后价值，这可能为胶质瘤患者的个体化治疗提供新的见解。IRGPs可能通过确定的26条功能途径发挥作用。
